Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02468557 · ClinicalTrials.gov registry record · Phase 1
Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma
A Phase 1 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT02468557 is a Phase 1 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 16 participants.
The verdict
NCT02468557, a Phase 1 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety of single agent idelalisib and to evaluate safety and define the maximum tolerated dose (MTD) of idelalisib in combination with chemotherapy in adults with metastatic pancreatic ductal adenocarcinoma.
Interventions
- DRUG Nab-paclitaxel
- DRUG Idelalisib
- DRUG mFOLFOX6
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-07-30 |
| Est. Completion | 2016-04-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02468557
The ClinicalTrials.gov registry entry for NCT02468557 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nab-paclitaxel is the first listed.
NCT02468557 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02468557 about?
NCT02468557 is a clinical study titled "Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma". The primary objective of this study is to evaluate the safety of single agent idelalisib and to evaluate safety and define the maximum tolerated dose (MTD) of idelalisib in combination with chemotherapy in adults with metastatic pancreatic ductal adenocarcinoma.
What is the current status of trial NCT02468557?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2015-07-30. Estimated completion is 2016-04-27.
What interventions are being tested in trial NCT02468557?
The interventions under investigation include: Nab-paclitaxel (DRUG), Idelalisib (DRUG), mFOLFOX6 (DRUG).
Who is sponsoring clinical trial NCT02468557?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.